Related Experiment Videos
Combined theophylline/beta-agonists maintenance therapy in chronic asthma
European Journal of Respiratory Diseases
|April 1, 1983
Summary
Adding slow-release theophylline (Theo-Dur) to standard asthma treatment improved peak expiratory flow (PEF) and reduced breathlessness. Patients preferred this combined therapy for enhanced asthma symptom relief.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Asthma management often involves beta-stimulants and steroids.
- The role of slow-release theophylline in augmenting standard therapy requires further evaluation.
Purpose of the Study:
- To assess the therapeutic value of adding slow-release theophylline (Theo-Dur) to existing beta-stimulant and steroid treatment for adult asthma.
- To evaluate the impact on asthma symptoms, lung function, and patient preference.
Main Methods:
- A randomized, double-blind, cross-over study involving 31 adult asthmatics.
- Participants received either 300 mg of theophylline or placebo twice daily for two 14-day periods.
- Daily peak expiratory flow (PEF), asthma symptoms, and aerosol consumption were recorded. Spirometry and theophylline levels were measured 12 hours post-dose.
Main Results:
- Theophylline addition resulted in a statistically significant increase in daily PEF values.
- A significant reduction in dyspnoea was observed, though cough and sputum volumes did not change.
- Patients expressed a preference for the combined treatment regimen.
- Morning spirometry results did not differ significantly between theophylline and placebo periods.
Conclusions:
- Slow-release theophylline, when added to beta-stimulant therapy, offers additional relief for asthma symptoms.
- This combination therapy provides benefits without a significant increase in adverse effects.
- Theophylline supplementation can be a valuable adjunct in managing adult asthma.